Dosing-related Saturation of Toxicity and Accelerated Drug Clearance with Pegaspargase Treatment.

[1]  H. D. de Groot-Kruseman,et al.  Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Downing,et al.  Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Relling,et al.  Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Loh,et al.  Genome‐Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy , 2017, Clinical pharmacology and therapeutics.

[5]  T. Ishida,et al.  The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[6]  C. Lanvers-Kaminsky,et al.  A population pharmacokinetic model for pegylated‐asparaginase in children , 2010, British journal of haematology.

[7]  T. Ishida,et al.  Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. , 2008, International journal of pharmaceutics.

[8]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[9]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[10]  M. Schrappe,et al.  Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols , 2000, British journal of haematology.